Bryan, Garnier & Co's News

ERYTech: Pfizer’s inotuzumab gets breakthrough therapy designation in ALL. Read-across for Erytech

BUY, Fair Value EUR42 (+42%)
News published on
October Tuesday 20, 2015


Pfizer announced it has received a Breakthrough Therapy Designation for inotuzumab ozogamicin following its phase III results as a monotherapy for adults suffering from ALL. We recognise that this antibody drug conjugate should be a new competitor for GRASPA, but we think the Street should not overestimate its ability to be a nuisance.


For more information, please contact marketing@bryangarnier.com